Cargando…
Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2)
PURPOSE OF REVIEW: Over the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector function. Understanding these changes will allow us to better understand allergic disease pathology and improve allergy treatment by modulating immune meta...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832094/ https://www.ncbi.nlm.nih.gov/pubmed/36520269 http://dx.doi.org/10.1007/s11882-022-01058-7 |
_version_ | 1784867989209743360 |
---|---|
author | Lin, Y.-J. Goretzki, A. Rainer, H. Zimmermann, J. Schülke, Stefan |
author_facet | Lin, Y.-J. Goretzki, A. Rainer, H. Zimmermann, J. Schülke, Stefan |
author_sort | Lin, Y.-J. |
collection | PubMed |
description | PURPOSE OF REVIEW: Over the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector function. Understanding these changes will allow us to better understand allergic disease pathology and improve allergy treatment by modulating immune metabolic pathways. As part two of a two-article series, this review reports on the recent studies investigating the metabolism of the cell types involved in allergies and discusses the initial application of these discoveries in allergy treatment. RECENT FINDINGS: The cell types involved in allergic reactions display pronounced and highly specific metabolic changes (here discussed for epithelial cells, APCs, ILC2s, mast cells, eosinophils, and Th2 cells). Currently, the first drugs targeting metabolic pathways are tested for their potential to improve allergy treatment. SUMMARY: Immune-metabolic changes observed in allergy so far are complex and depend on the investigated disease and cell type. However, our increased understanding of the underlying principles has pointed to several promising target molecules that are now being investigated to improve allergy treatment. |
format | Online Article Text |
id | pubmed-9832094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-98320942023-01-12 Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) Lin, Y.-J. Goretzki, A. Rainer, H. Zimmermann, J. Schülke, Stefan Curr Allergy Asthma Rep Allergens (RK Bush and S Vieths, Section Editors) PURPOSE OF REVIEW: Over the last years, we have learned that the metabolic phenotype of immune cells is closely connected to the cell’s effector function. Understanding these changes will allow us to better understand allergic disease pathology and improve allergy treatment by modulating immune metabolic pathways. As part two of a two-article series, this review reports on the recent studies investigating the metabolism of the cell types involved in allergies and discusses the initial application of these discoveries in allergy treatment. RECENT FINDINGS: The cell types involved in allergic reactions display pronounced and highly specific metabolic changes (here discussed for epithelial cells, APCs, ILC2s, mast cells, eosinophils, and Th2 cells). Currently, the first drugs targeting metabolic pathways are tested for their potential to improve allergy treatment. SUMMARY: Immune-metabolic changes observed in allergy so far are complex and depend on the investigated disease and cell type. However, our increased understanding of the underlying principles has pointed to several promising target molecules that are now being investigated to improve allergy treatment. Springer US 2022-12-15 2023 /pmc/articles/PMC9832094/ /pubmed/36520269 http://dx.doi.org/10.1007/s11882-022-01058-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Allergens (RK Bush and S Vieths, Section Editors) Lin, Y.-J. Goretzki, A. Rainer, H. Zimmermann, J. Schülke, Stefan Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) |
title | Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) |
title_full | Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) |
title_fullStr | Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) |
title_full_unstemmed | Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) |
title_short | Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment — Cell Type-Specific Findings (Part 2) |
title_sort | immune metabolism in th2 responses: new opportunities to improve allergy treatment — cell type-specific findings (part 2) |
topic | Allergens (RK Bush and S Vieths, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832094/ https://www.ncbi.nlm.nih.gov/pubmed/36520269 http://dx.doi.org/10.1007/s11882-022-01058-7 |
work_keys_str_mv | AT linyj immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2 AT goretzkia immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2 AT rainerh immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2 AT zimmermannj immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2 AT schulkestefan immunemetabolisminth2responsesnewopportunitiestoimproveallergytreatmentcelltypespecificfindingspart2 |